Loading...
XNASNBTX
Market cap138mUSD
Dec 24, Last price  
2.94USD
1D
-1.34%
1Q
-40.24%
IPO
-82.69%
Name

Nanobiotix SA

Chart & Performance

D1W1MN
XNAS:NBTX chart
P/E
—
P/S
4.43
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.47%
Rev. gr., 5y
203.88%
Revenues
30m
+529.36%
1,360,31474,153184,938967,500265,5431,558,101251,968116,00068,00050,00010,0004,776,00030,058,000
Net income
-40m
L-30.40%
-5,246,579-5,330,896-8,144,920-9,556,525-17,003,084-21,880,511-26,143,249-29,896,000-50,915,000-33,623,000-47,004,000-57,043,000-39,700,000
CFO
-12m
L-66.38%
-4,873,240-3,785,750-6,830,566-8,564,825-16,820,489-18,283,766-21,032,806-25,985,000-41,169,000-27,538,000-29,872,000-37,104,000-12,476,000
Earnings
May 20, 2025

Profile

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
URL
https://www.nanobiotix.com
IPO date
Oct 29, 2012
Employees
102
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
30,058
529.36%
4,776
47,660.00%
10
-80.00%
Cost of revenue
60,057
51,101
49,812
Unusual Expense (Income)
NOPBT
(29,999)
(46,325)
(49,802)
NOPBT Margin
Operating Taxes
120
10
5
Tax Rate
NOPAT
(30,119)
(46,335)
(49,807)
Net income
(39,700)
-30.40%
(57,043)
21.36%
(47,004)
39.80%
Dividends
Dividend yield
Proceeds from repurchase of equity
60,154
(306)
BB yield
Debt
Debt current
5,022
4,560
8,204
Long-term debt
50,625
54,138
44,335
Deferred revenue
Other long-term liabilities
325
270
318
Net debt
(19,636)
17,310
(31,480)
Cash flow
Cash from operating activities
(12,476)
(37,104)
(29,872)
CAPEX
(328)
(93)
(233)
Cash from investing activities
(349)
138
(242)
Cash from financing activities
46,771
(5,651)
(5,180)
FCF
(29,106)
(45,269)
(49,737)
Balance
Cash
75,283
41,388
83,921
Long term investments
98
Excess cash
73,780
41,149
84,018
Stockholders' equity
(314,358)
(282,577)
(228,774)
Invested Capital
363,404
302,375
296,824
ROIC
ROCE
EV
Common stock shares outstanding
36,928
34,852
34,733
Price
Market cap
EV
EBITDA
(28,486)
(44,825)
(48,242)
EV/EBITDA
Interest
7,982
5,837
590
Interest/NOPBT